Monitoring disease activity in antineutrophil antibody-associated vasculitis.
Scand J Immunol
; 98(1): e13284, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-37132459
ABSTRACT
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) comprises a group of multisystem disorders with alternating periods of relapse and remission. Beyond that, a smouldering progress during apparently clinically silent phases often develops. AAVs are subgrouped in microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and renal limited vasculitis (RLV). ANCA are hallmark of this disease entity, although they are not always present. Despite the simplification of treatment, fundamental aspects concerning assessment of its efficacy and its adaptation to encountered complications or to the relapsing/remitting/subclinical disease course remain still unknown. Through the advances in pathogenesis and pathophysiology of AAV a reliable biomarker-based monitoring and treatment algorithm has not been established and disease management follows not infrequently a "trial and error" approach. Here, we overviewed the most interesting biomarkers reported so far.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Síndrome de Churg-Strauss
/
Granulomatosis con Poliangitis
/
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos
/
Poliangitis Microscópica
Tipo de estudio:
Diagnostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Scand J Immunol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Alemania